CLYM
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Supports a bullish reading. Current ratio 15.16 · operating margin 0.0%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Supports a bullish reading. Interesting trend — weekly bias up
VENTE TOTALE: 100 000 titres (~1 366 820,00 $ US)
- Insiders
- Thomas Stephen Basil
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,366,820
Avg sell (VWAP, 90d window) $13.55 vs last close $12.52 (-7.6%)
- Last activity
- 2026-09-15
- Liquidity
- Liquid $23,012,391/day · 20d vol
- Last synced
-
2026-09-23 21:10:16
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-15 | Thomas Stephen Basil | Sell | 100,000 | $13.67 | $1,366,820 | Form 4 |
| 2026-06-29 | Brennan Aoife | Sell | 30,902 | $13.17 | $406,979 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-20
CLYM presents a deeply distressed financial profile with zero revenue, persistent negative cash flows, and no operational viability, making the fundamental foundation extremely fragile.
The first sentence of the analysis written for CLYM on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 15.156 | 31.408 | 38.918 | 22.042 | 24.582 | |
| Quick Ratio | 15.156 | 31.408 | 38.918 | 22.042 | 24.582 | |
| Solvency Ratio | -8.220 | -13.927 | -12.237 | -7.208 | -7.864 | |
| Cash Ratio | 5.110 | 17.690 | 32.867 | 7.149 | 7.780 | |
| Price To Earnings Ratio | -4.545 | -1.176 | -6.023 | -4.552 | -1.847 | |
| Price To Earnings Growth Ratio | 0.107 | -0.066 | 0.247 | 0.077 | -0.016 | |
| Forward Price To Earnings Growth Ratio | 0.107 | -0.066 | 0.247 | 0.077 | -0.016 | |
| Price To Earnings Diluted Ratio | -4.545 | -1.176 | -6.023 | -4.552 | -1.847 | |
| Price To Earnings Diluted Growth Ratio | 0.107 | -0.066 | 0.247 | 0.077 | -0.016 | |
| Price To Book Ratio | 1.690 | 0.409 | 1.964 | 1.601 | 0.574 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.973 | -5.571 | -10.258 | -5.513 | -2.661 | |
| Price To Operating Cash Flow Ratio | -4.990 | -5.571 | -10.258 | -5.513 | -2.661 | |
| Debt To Assets Ratio | 0.003 | 0.002 | 0.003 | 0.004 | 0.000 | |
| Debt To Equity Ratio | 0.003 | 0.003 | 0.003 | 0.004 | 0.000 | |
| Debt To Capital Ratio | 0.003 | 0.003 | 0.003 | 0.004 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.045 | 1.025 | 1.027 | 1.049 | 1.036 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -7.783 | -3.156 | -7.271 | -6.129 | -5.981 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | 1.000 | 1.000 | 1.000 | 1.000 | |
| Debt Service Coverage Ratio | -233.414 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -212.328 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -100.473 | -29.252 | -59.023 | -77.852 | 0.000 | |
| Capital Expenditure Coverage Ratio | -292.237 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -292.237 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.951 | 0.000 | -3.376 | -3.601 | -1.034 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 15.156 | ▼-16.252 | ▼-11.265 |
| Quick Ratio | 15.156 | ▼-16.252 | ▼-11.265 |
| Solvency Ratio | -8.220 | ▲5.707 | ▲1.671 |
| Cash Ratio | 5.109 | ▼-12.580 | ▼-9.009 |
| Price To Earnings Ratio | -4.545 | ▼-3.369 | ▼-0.917 |
| Price To Earnings Growth Ratio | 0.107 | ▲0.173 | ▲0.037 |
| Forward Price To Earnings Growth Ratio | 0.107 | ▲0.173 | ▲0.037 |
| Price To Earnings Diluted Ratio | -4.545 | ▼-3.369 | ▼-0.917 |
| Price To Earnings Diluted Growth Ratio | 0.107 | ▲0.173 | ▲0.037 |
| Price To Book Ratio | 1.690 | ▲1.281 | ▲0.443 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -4.973 | ▲0.598 | ▲0.822 |
| Price To Operating Cash Flow Ratio | -4.990 | ▲0.581 | ▲0.808 |
| Debt To Assets Ratio | 0.003 | ▲0.001 | ▲0.001 |
| Debt To Equity Ratio | 0.003 | ▲0.001 | ▲0.001 |
| Debt To Capital Ratio | 0.003 | ▲0.001 | ▲0.001 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.045 | ▲0.020 | ▲0.009 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -7.783 | ▼-4.627 | ▼-1.719 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.003 | ▲0.003 | ▲0.003 |
| Debt Service Coverage Ratio | -233.414 | ▼-233.414 | ▼-186.731 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -212.328 | ▼-212.328 | ▼-169.863 |
| Operating Cash Flow Coverage Ratio | -100.473 | ▼-71.221 | ▼-47.153 |
| Capital Expenditure Coverage Ratio | -292.237 | ▼-292.237 | ▼-233.789 |
| Dividend Paid And Capex Coverage Ratio | -292.237 | ▼-292.237 | ▼-233.789 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.951 | ▼-3.951 | ▼-1.559 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $271.2M | $86.7M | $211.3M | $206.0M | $96.0M | |
| Enterprise value | $236.1M | -$3K | $118.5M | $162.9M | $49.1M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.34x | 0.00x | -5.75x | -4.36x | -1.36x | |
| EV / Free cash flow | -4.33x | 0.00x | -5.75x | -4.36x | -1.36x | |
| EV / EBITDA | -3.95x | 0.00x | -3.38x | -3.60x | -1.03x | |
| Net debt / EBITDA | 0.59x | 2.86x | 2.64x | 0.95x | 0.99x | |
| Current ratio | 15.16x | 31.41x | 38.92x | 22.04x | 24.58x | |
| Income quality | 0.91x | 0.21x | 0.59x | 0.83x | 0.76x | |
| Graham net-net | $1 | $3 | $4 | $5 | $11 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 243.4% | 100.0% | 100.0% | 100.0% | |
| Working capital | $98.9M | $149.9M | $107.4M | $128.3M | $142.2M | |
| Invested capital | $99.7M | $150.4M | $107.6M | $128.8M | $142.2M | |
| Return on assets | -35.7% | -34.0% | -31.8% | -33.5% | -27.4% | |
| Operating ROA | -35.3% | -50.1% | -32.8% | -29.3% | -36.1% | |
| Return on tangible assets | -35.7% | -34.0% | -31.8% | -33.5% | -27.4% | |
| Return on equity | -37.3% | -34.9% | -32.6% | -35.2% | -28.4% | |
| Return on invested capital | -42.2% | -38.6% | -37.3% | -34.9% | -21.3% | |
| Return on capital employed | -42.2% | -38.6% | -37.4% | -35.0% | -21.3% | |
| Earnings yield | -22.1% | -85.2% | -16.6% | -22.0% | -49.5% | |
| Free cash flow yield | -20.1% | -18.0% | -9.7% | -18.1% | -37.6% | |
| Capex / Op. cash flow | -0.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 191.8% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 8538d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | -8538d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+212.9%EV / Sales n/aEV / EBITDA ▼-3922822.8%EV / Op. cash flow ▼-4.344Earnings yield ▲+0.632
Profitability
Return on equity ▼-0.024Return on assets ▼-0.017Return on invested capital ▼-0.035Return on capital employed ▼-0.036Operating ROA ▲+0.148Income quality ▲+0.698Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-16.252Net debt / EBITDA ▼-2.267Working capital ▼-51076000.000Invested capital ▼-50773000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+182.6%EV / Sales n/aEV / EBITDA ▼-282.3%EV / Op. cash flow ▼-2.983Earnings yield ▲+0.274
Profitability
Return on equity ▼-0.089Return on assets ▼-0.083Return on invested capital ▼-0.208Return on capital employed ▼-0.209Operating ROA ▲+0.008Income quality ▲+0.148Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-9.426Net debt / EBITDA ▼-0.400Working capital ▼-43356000.000Invested capital ▼-42563000.000Intangibles / Total assets n/a
Employee count
No employee-count data synced.
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-09-03 Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.
- 2026-09-03 Climb Bio''s Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.
- 2026-09-03 Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 2027, Phase 3 study initiation in 2027 Company to host R&D Spotlight Webcast today, September 3 at 8:00 a.m. ET WELLESLEY HILLS, Mass.
- 2026-09-02 Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
- 2026-07-28 Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgrade Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report) shot up 10.9% on Monday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.25 and last traded at $14.24. Approximately 228,260 shares changed hands during trading, a
- 2026-07-28 Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgrade Climb Bio, Inc. (NASDAQ: CLYM - Get Free Report)''s stock price reached a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $17.00 to $20.00. Wedbush currently has an outperform rating on the stock. Climb Bio traded as high as $14.42 and last traded at $12.79, with a
- 2026-07-23 Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatility